Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 5
1959 11
1960 10
1961 11
1962 14
1963 25
1964 22
1965 13
1966 19
1967 23
1968 39
1969 22
1970 18
1971 27
1972 11
1973 18
1974 16
1975 10
1976 13
1977 11
1978 8
1979 13
1980 9
1981 11
1982 10
1983 4
1984 8
1985 9
1986 3
1987 6
1988 3
1989 6
1990 4
1992 5
1993 6
1994 6
1995 1
1996 4
1997 6
1998 13
1999 8
2000 11
2001 9
2002 15
2003 13
2004 12
2005 16
2006 17
2007 13
2008 15
2009 15
2010 16
2011 23
2012 26
2013 31
2014 27
2015 34
2016 54
2017 54
2018 84
2019 71
2020 142
2021 211
2022 353
2023 445
2024 501
2025 648
2026 224

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,153 results

Results by year

Filters applied: . Clear all
Page 1
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. Lowe H, et al. Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948. Molecules. 2021. PMID: 34063505 Free PMC article. Review.
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment …
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as …
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.
Dinis-Oliveira RJ. Dinis-Oliveira RJ. Drug Metab Rev. 2017 Feb;49(1):84-91. doi: 10.1080/03602532.2016.1278228. Epub 2017 Jan 31. Drug Metab Rev. 2017. PMID: 28074670 Review.
Psilocybin and psilocin are controlled substances in many countries. These are the two main hallucinogenic compounds of the "magic mushrooms" and both act as agonists or partial agonists at 5-hydroxytryptamine (5-HT)(2A) subtype receptors. ...This review aims to discuss me …
Psilocybin and psilocin are controlled substances in many countries. These are the two main hallucinogenic compounds of the "magic mu …
Psilocybin: from ancient magic to modern medicine.
Nichols DE. Nichols DE. J Antibiot (Tokyo). 2020 Oct;73(10):679-686. doi: 10.1038/s41429-020-0311-8. Epub 2020 May 12. J Antibiot (Tokyo). 2020. PMID: 32398764 Review.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. ...At present, assuming that the early clinical studies can be validated by larger studies, psilocybin is poised to make a signific …
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms …
Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Carhart-Harris R, et al. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. N Engl J Med. 2021. PMID: 33852780 Clinical Trial.
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. ...Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks a …
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatment …
Psilocybin for Trauma-Related Disorders.
Khan AJ, Bradley E, O'Donovan A, Woolley J. Khan AJ, et al. Curr Top Behav Neurosci. 2022;56:319-332. doi: 10.1007/7854_2022_366. Curr Top Behav Neurosci. 2022. PMID: 35711024 Review.
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. .. …
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin …
The pharmacology of psilocybin.
Passie T, Seifert J, Schneider U, Emrich HM. Passie T, et al. Addict Biol. 2002 Oct;7(4):357-64. doi: 10.1080/1355621021000005937. Addict Biol. 2002. PMID: 14578010 Review.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide. ...Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until rece …
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed world …
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Carhart-Harris RL, et al. Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17. Lancet Psychiatry. 2016. PMID: 27210031 Free article. Clinical Trial.
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. ...This trial is registered with ISRCTN, number I …
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored fo …
Psilocybin and Other Classic Psychedelics in Depression.
Nutt DJ, Peill JM, Weiss B, Godfrey K, Carhart-Harris RL, Erritzoe D. Nutt DJ, et al. Curr Top Behav Neurosci. 2024;66:149-174. doi: 10.1007/7854_2023_451. Curr Top Behav Neurosci. 2024. PMID: 37955822 Review.
Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT(2A) receptor such as psilocybin …
Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders includ …
Impact of psilocybin on cognitive function: A systematic review.
Meshkat S, Tello-Gerez TJ, Gholaminezhad F, Dunkley BT, Reichelt AC, Erritzoe D, Vermetten E, Zhang Y, Greenshaw A, Burback L, Winkler O, Jetly R, Mayo LM, Bhat V. Meshkat S, et al. Psychiatry Clin Neurosci. 2024 Dec;78(12):744-764. doi: 10.1111/pcn.13741. Epub 2024 Oct 1. Psychiatry Clin Neurosci. 2024. PMID: 39354706 Free PMC article.
In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic databases from inception to January 2024, identifying 20 articles involving 2,959 participants. ...The observed mixed findings underscore th …
In this systematic review, we assessed psilocybin's effect on cognitive function through a comprehensive search of electronic …
Increased global integration in the brain after psilocybin therapy for depression.
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Daws RE, et al. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411074 Clinical Trial.
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin …
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients wit …
3,153 results